Abstract |
A multicenter, open-label trial in Japan examined the efficacy, safety, and optimal dose of monatepil (AJ-2615) as monotherapy and in combination therapy with angiotensin-converting enzyme ( ACE) inhibitors or beta-blockers. Patients with essential hypertension who had never been treated or had been refractory to conventional antihypertensive agents were enrolled in the trial. During a 4-week control period patients assigned to monotherapy received placebo and those assigned to combination therapy received an ACE inhibitor or beta-blocker and placebo. Patients with systolic blood pressure (BP) > or = 160 mm Hg and diastolic BP > or = 95 mm Hg at the end of the control period were enrolled in the study. The initial dose of monatepil was 30 mg/day in monotherapy and 15 mg/day in combination therapy; the daily dose was titrated to 60 mg/day according to the antihypertensive response. The treatment period was 8 to 12 weeks. Blood pressure decreased from 168 +/- 8/100 +/- 6 to 142 +/- 9/85 +/- 7 mm Hg (SD) with monatepil monotherapy, from 171 +/- 11/102 +/- 6 to 141 +/- 9/84 +/- 6 mm Hg in combination with ACE inhibitors, and from 175 +/- 13/102 +/- 7 to 153 +/- 21/91 +/- 9 mm Hg in combination with beta-blockers (P < .001). When patients in whom mean BP decreased by > or = 13 mm Hg were defined as responders, the response rate was 80.4%, 78.1%, and 51.6% in the respective groups.(ABSTRACT TRUNCATED AT 250 WORDS)
|
Authors | M Ishii, O Iimura, K Yoshinaga, K Abe, Y Inagaki, S Yagi, K Kuramoto, N Kajiwara, T Saruta, M Kuramochi |
Journal | American journal of hypertension
(Am J Hypertens)
Vol. 7
Issue 10 Pt 2
Pg. 141S-145S
(Oct 1994)
ISSN: 0895-7061 [Print] United States |
PMID | 7826564
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Adrenergic beta-Antagonists
- Calcium Channel Blockers
- Dibenzothiepins
- Piperazines
- Cholesterol
- Peptidyl-Dipeptidase A
- monatepil
|
Topics |
- Adrenergic beta-Antagonists
(administration & dosage, therapeutic use)
- Adult
- Aged
- Blood Pressure
(drug effects)
- Calcium Channel Blockers
(administration & dosage, therapeutic use)
- Cholesterol
(blood)
- Dibenzothiepins
(administration & dosage, therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Hypertension
(blood, drug therapy)
- Male
- Middle Aged
- Peptidyl-Dipeptidase A
(administration & dosage, therapeutic use)
- Pilot Projects
- Piperazines
(administration & dosage, therapeutic use)
|